Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P01241
UPID:
SOMA_HUMAN
Alternative names:
Growth hormone; Growth hormone 1; Pituitary growth hormone
Alternative UPACC:
P01241; A6NEF6; Q14405; Q16631; Q5EB53; Q9HBZ1; Q9UMJ7; Q9UNL5
Background:
Somatotropin, also known as Growth Hormone (GH), plays a pivotal role in growth control by stimulating IGF-1 secretion from the liver and other tissues. It promotes the differentiation and proliferation of myoblasts, enhances amino acid uptake, and boosts protein synthesis in muscle and other tissues.
Therapeutic significance:
Somatotropin is crucial in treating Growth Hormone Deficiencies (GHD), including isolated GHD types 1A, 1B, and 2, and Kowarski syndrome. These conditions, characterized by short stature and growth failure, respond positively to GH therapy, highlighting its therapeutic potential.